The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.
An article from
Dive Brief
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.
Published June 10, 2026
Sanofi on June 10, 2026 said an immune drug called riliprubart failed a late-stage study in chronic inflammatory demyelinating polyneuropathy.
Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sanofi (NASDAQ:SNY)
Sanofi encerra estudo de fase avançada de medicamento experimental
"Je me considère comme un phénix" : un nouveau traitement permet de ralentir la progression de la sclérose en plaques
Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study - Novartis
Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the…
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst…
A farmacêutica francesa declarou que avaliará se dará continuidade a outros estudos em andamento para o fármaco, chamado…
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet…
La società ha annunciato un ulteriore rinvio della decisione della FDA statunitense sul tolebrutinib e il fallimento di uno…
Pubblicati i risultati contrastanti di due studi sull’itepekimab, un anticorpo monoclonale testato su ex fumatori affetti da…
